Gastrointestinal Malignancies

Share

Program Content

Activities

  • Conference to Clinic: Gastrointestinal Cancers
    Conference to Clinic: Gastrointestinal Cancers
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 20, 2023

  • Conference to Clinic: Gastrointestinal Malignancies
    Conference to Clinic: Expert Analysis of the Top Gastrointestinal Malignancies Abstracts From the 2023 Oncology Meeting in Chicago
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 29, 2023

    Expires: June 28, 2024

  • ASCO 2023 GI Cancers
    Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2023 ASCO Annual Meeting
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 29, 2023

    Expires: August 28, 2024

Activities

ATTRACTION-5
ATTRACTION-5: Phase III Study of Adjuvant Nivolumab + Chemotherapy After Gastrectomy for Pathologic Stage III Gastric or Gastroesophageal Junction Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

NORPACT-1
NORPACT-1: Neoadjuvant FOLFIRINOX vs Upfront Surgery in Resectable Pancreatic Head Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

KEYNOTE-966 HRQoL
KEYNOTE-966: Health-Related Quality-of-Life Outcomes With Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy in Advanced Biliary Tract Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2023

Zanidatamab for HER2+ BTC
HERIZON-BTC-01: Zanidatamab, a HER2-Targeted Bispecific Antibody, in Previously Treated HER2‑Amplified Biliary Tract Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

Tucatinib + Trastuzumab in HER2+ BTC
Tucatinib + Trastuzumab for Previously Treated Advanced HER2+ Biliary Tract Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

AtezoTRIBE Update
AtezoTRIBE: Updated Results of First-line Treatment With FOLFOXIRI + Bevacizumab ± Atezolizumab for Unresectable Metastatic Colorectal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

PROSPECT
PROSPECT: Neoadjuvant Chemoradiation vs FOLFOX With Selective Chemoradiation for Locally Advanced Rectal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

FIRE-4 Liquid Biopsy Analysis
FIRE-4: RAS/BRAF Mutation by Liquid Biopsy and Benefit From First-line FOLFIRI + Cetuximab in Patients With RAS-WT Metastatic Colorectal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2023

Faculty

cover img faculity

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

cover img faculity

Rachna Shroff, MD, MS

Professor of Medicine
Interim Chief, Division of Hematology/Oncology
University of Arizona Cancer Center
Tucson, Arizona

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp., Novocure, and Seagen.

Merck Sharp & Dohme Corp.

Novocure

Seagen